Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Li Ding

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1517-2975; OpenAlex author ID A5100449520; NIH RePORTER profile ID 9766169. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
2
Labs led
1
Collaborators
30
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 3 papers, 1 grant · 2024: 2 papers · 2025: none · 2026: 1 grant

Papers 8

  1. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Co-author DOI 10.1038/s41467-024-46811-w↗
  2. Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-23-0428↗
  3. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. Co-author DOI 10.1038/s41590-023-01579-x↗
  4. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. Co-author DOI 10.1084/jem.20212062↗
  5. Single-cell transcriptomics reveals long noncoding RNAs associated with tumor biology and the microenvironment in pancreatic cancer. Co-author DOI 10.1093/narcan/zcad055↗
  6. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Last author DOI 10.1038/s41588-022-01157-1↗
  7. Clinical Analysis of Bloodstream Infection of Escherichia coli in Patients with Pancreatic Cancer from 2011 to 2019. Co-author DOI 10.1155/2022/1338188↗
  8. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.cell.2021.08.023↗

Grants 2

  1. The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity U01CA284086↗
  2. Data Processing, Analysis and Modeling Unit U2CCA233303↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ryan C Fields · 5 shared papers, 2 shared grants, 2023–2026 · strength 2.31
  2. David G DeNardo · 4 shared papers, 1 shared grant, 2023–2026 · strength 1.60
  3. Samuel Achilefu · 1 shared grant, 2023 · strength 0.53
  4. William E. Gillanders · 1 shared grant, 2023 · strength 0.53
  5. John M. Baer · 3 shared papers, 2023–2024 · strength 0.45
  6. Liang‐I Kang · 2 shared papers, 2023–2024 · strength 0.32
  7. Varintra E. Lander · 2 shared papers, 2023–2024 · strength 0.31
  8. Jad I. Belle · 2 shared papers, 2023–2024 · strength 0.31
  9. William G. Hawkins · 2 shared papers, 2023–2024 · strength 0.29
  10. Paarth B. Dodhiawala · 2 shared papers, 2023–2024 · strength 0.29
  11. Kian‐Huat Lim · 2 shared papers, 2023–2024 · strength 0.29
  12. Chong Zuo · 2 shared papers, 2023 · strength 0.28
  13. Christopher A Maher · 1 shared paper, 2023 · strength 0.18
  14. Ha X. Dang · 1 shared paper, 2023 · strength 0.18
  15. Blake E. Sells · 1 shared paper, 2024 · strength 0.17
  16. Paolo Provenzano · 1 shared paper, 2024 · strength 0.17
  17. Guhan Qian · 1 shared paper, 2024 · strength 0.17
  18. Hyun Jee Kim · 1 shared paper, 2024 · strength 0.17
  19. Yueguo Li · 1 shared paper, 2022 · strength 0.16
  20. Changsen Bai · 1 shared paper, 2022 · strength 0.16
  21. Li Ren · 1 shared paper, 2022 · strength 0.16
  22. Patrick M. Grierson · 1 shared paper, 2024 · strength 0.15
  23. Ashenafi Shiferaw Bulle · 1 shared paper, 2024 · strength 0.15
  24. Vikas Somani · 1 shared paper, 2024 · strength 0.15
  25. Sapana Bansod · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.